IDEXX Laboratories, Inc. (IDXX) Stock Price Today
Key Stats
- $40.91BMarket Cap
- 331,123Volume
- HealthSector
- $766.6852W High
- $504.7052W Low
- 46 DaysTypical Hold Time
- $41.81BEnterprise Value
- -Div Yield
- -Trading Activity
Track IDEXX Laboratories, Inc. (IDXX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, IDEXX Laboratories, Inc. has traded between a low of $504.7 and a high of $766.68, highlighting its annual price range. Buy and sell IDEXX Laboratories, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Most Recent News
Several high-volume stocks plunge sharply amid profit-taking despite positive updates.
Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...

Stocks jump on clinical trial updates, acquisition deals, and trading momentum.
Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...

Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.